SCHEMBL6315874

SCHEMBL6315874

NC(=O)c1c(-c2cccnc2)noc1NC(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.53
TSHR P16473 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
PDGFRB P09619 1/20 0.52
KDR P35968 1/20 0.52
ALOX15 P16050 1/20 0.51
CASP1 P29466 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HSD17B10 Q99714 1/20 0.51
PIKFYVE Q9Y2I7 3/20 0.50
BRAF P15056 5/20 0.49
CSF1R P07333 4/20 0.48
ABL1 P00519 1/20 0.48
BCR P11274 1/20 0.48
PTGS1 P23219 1/20 0.47
TEK Q02763 1/20 0.46
TRPV1 Q8NER1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318236 0.90 NTRK1 (0.53) TSHRMEN1KMT2AABL1BCR
SCHEMBL6321264 0.89 LMNA (0.55) LMNATSHRPDGFRBKDRALOX15
SCHEMBL28750988 0.86 LMNA (0.46) LMNATSHRMEN1KMT2APDGFRB
SCHEMBL6322587 0.85 MAPT (0.51) LMNAMEN1KMT2ACSF1R
SCHEMBL6323026 0.85 POLB (0.56) LMNAMEN1KMT2ABRAFCSF1R
SCHEMBL6318671 0.85 KDM4E (0.56) LMNAMEN1KMT2ABRAFCSF1R
SCHEMBL6316770 0.82 LMNA (0.53) LMNAMEN1KMT2APDGFRBKDR
SCHEMBL6316651 0.82 ALDH1A1 (0.57) LMNATSHRMEN1KMT2AHSD17B10
SCHEMBL6316051 0.82 RAB9A (0.54) LMNAMEN1KMT2ATRPV1
SCHEMBL6315761 0.81 CYP11B1 (0.52) LMNAPDGFRBABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 LMNA 3334/4885TSHR 3971/4885MEN1 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.